Charles River Laboratories International (CRL) opened 2026 with Q1 revenue of US$995.8 million and a basic EPS loss of US$0.30, alongside net income excluding extra items of a US$14.8 million loss, with the stock trading around US$181.68. The company has seen quarterly revenue move from US$984.2 million in Q1 2025 to just over US$1.0 billion across several recent periods, while basic EPS has swung between a profit of about US$1.11 and a much larger loss of about US$5.62. This has left margins under pressure even as the top line holds near the US$1.0 billion mark.

See our full analysis for Charles River Laboratories International.

With the headline numbers on the table, the next step is to see how these results line up with the widely discussed risk and reward narratives that have formed around Charles River Laboratories International over the past year.

Losses Persist On US$4.0b Trailing Revenue Base

• Over the last 12 months, Charles River generated about US$4.0b in revenue but reported a net loss excluding extra items of US$184.7 million, and trailing basic EPS of US$3.76 loss.
• Consensus narrative highlights expected earnings of US$483.2 million and an 11.0% margin in a few years, yet the current trailing loss and negative margins show that, for now, profitability is still a work in progress compared with those expectations.
  • Analysts are looking for revenue to grow around 2.8% a year, which is modest next to the referenced 11.4% US market growth rate. At the same time, the trailing numbers show revenue holding close to US$4.0b rather than expanding quickly.
  • The move from a recent quarterly net income excluding extra items loss of US$14.8 million back toward positive earnings would need a clear shift in either pricing, mix, or costs. That shift is not yet evident in the trailing financials.

EPS Swings From US$1.11 Profit To US$5.62 Loss

• Over the past few quarters, basic EPS has ranged from a profit of about US$1.11 in Q3 2025 to a loss of about US$5.62 in Q4 2025, with Q1 2026 landing at a smaller US$0.30 loss.
• Bears argue that structural pressures from alternative testing methods and client consolidation could keep earnings volatile, and these large EPS swings underline how sensitive results have been to shifts in demand and pricing.
  • Bearish commentary points to potential erosion in demand for animal based research as NAMs and other technologies develop, while the recent losses, including the Q4 2025 net income excluding extra items loss of US$276.6 million, give that concern clear numerical backing.
  • Concerns about pricing pressure from larger, consolidated clients line up with the pattern of revenue hovering near US$1.0b per quarter while EPS has moved sharply in both directions. This suggests that similar revenue levels have produced very different earnings outcomes.

On top of these swings, some investors focus on whether the more cautious view better fits a company that is still reporting losses despite stable revenue, and look closely at how future contracts and cost actions might change that picture over time. 🐻 Charles River Laboratories International Bear Case

High Debt And 2.2x P/S Frame Valuation Debate

• The stock trades on a P/S of 2.2x against a cited Life Sciences industry average of 3.4x, while the business carries what is described as a high level of debt and remains loss making over the trailing 12 months.
• Bullish investors see a path to earnings growth of about 32.3% a year and a return to profitability, and the current P/S discount is often used to argue that the market is not fully pricing in that recovery.
  • Bulls point to forecasts for revenue to grow around 3.1% annually in their more optimistic case, which is slightly above the 2.8% consensus expectation yet still relatively modest, so much of their argument rests on margin improvement from the current negative level.
  • The contrast between the current share price of US$181.68 and an analyst price target of US$201.33 sets up a valuation gap that bullish views link to future earnings improvement, even though trailing net income excluding extra items is still a loss of US$184.7 million.

For readers who want to see how this potential upside case is built from detailed earnings and margin assumptions, it helps to step through the full bullish narrative alongside the latest reported numbers. 🐂 Charles River Laboratories International Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Charles River Laboratories International on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls and bears both making strong cases, it helps to check the underlying figures yourself and decide how the current risks and rewards stack up for your own portfolio, starting with the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Charles River Laboratories International is working through earnings volatility, trailing losses on a US$4.0b revenue base and a high debt load that keeps risk elevated.

If you want fewer balance sheet and earnings surprises than this profile suggests, consider shifting some research time toward the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.